Obesity
Conditions
Brief summary
This research project will provide insight into the efficacy and safety of aspiration therapy in the management of obesity and its comorbidities in the Asian population, and will determine if there is a role for this novel endoscopic device in the treatment algorithm of obesity in the investigators' local regions.
Detailed description
Obesity is a major global health problem and Asians are equally affected. According to the latest Behavioural Risk Factor Survey in 2014, 20.8% of adults in Hong Kong have body mass index (BMI) belonging to the obese category. Obesity is associated with a multitude of medical and psychological comorbidities that could cumulate in increased healthcare costs and impaired quality of life. As such, an effective treatment strategy for obesity is imperative. Sustainable weight reduction by lifestyle measures alone is often difficult if not impossible. Pharmacotherapy can provide additional weight reduction when used as an adjunct to lifestyle intervention but the efficacy is modest. The most effective method for weight reduction to date is bariatric surgery but this is limited by its invasiveness and irreversibility. The limitations of current obesity treatment has led to an increased interest in endoscopic treatment, which may be more effective than pharmacotherapy and less invasive and more reversible than bariatric surgery. The AspireAssist® Aspiration Therapy System is a novel endoscopic therapy developed by Aspire Bariatrics Inc. (King of Prussia, United States) for treatment of obesity. The system takes advantage of percutaneous endoscopic gastrostomy (PEG) tube technology to induce weight reduction by aspirating a portion of ingested meals from the stomach. In a pilot study involving 18 Caucasian obese subjects randomly assigned in a 2:1 ratio to aspiration therapy group and lifestyle therapy only group, the weight reduction was 18.6% +/- 2.3% and 5.9% +/- 5.0% respectively. The present study aims to investigate the effectiveness and safety of this device in Asian subjects.
Interventions
DEVICEAspiration Therapy (AspireAssist®)
Use of the AspireAssist device in aspiration therapy
BEHAVIORALLifestyle Therapy
Lifestyle therapy is a behavioral, diet and physical activity education program
Sponsors
Aspire Bariatrics, Inc.
The University of Hong Kong
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
1. Measured body mass index (BMI) of 27.5-55.0 kg/m2 at time of screening. 2. 21- 65 years of age (inclusive) at time of screening. 3. Failed attempt for a duration equal to 3-months at weight loss by alternative approaches (e.g. supervised or unsupervised diets, exercise, behavioral modification programs) 4. Stable weight (\<3% change in self-reported weight) over the previous 3 months at time of screening. 5. Women of childbearing potential who agree to use at least one form of birth control (prescription hormonal contraceptives, diaphragm, intrauterine device (IUD), condoms with or without spermicide, or voluntary abstinence) from time of study enrollment through study exit 6. Willing and able to provide informed consent and comply with the protocol.
Exclusion criteria
1. Evidence of an eating disorder or major depression 2. History of gastrointestinal disease or previous gastric surgery that would increase the risk of the AspireAssist® Tube (A-Tube) placement 3. Severe co-existing medical diseases or malignancies 4. Bleeding tendency (low platelet, coagulopathy including being on anti-coagulants) 5. Pregnant/lactating
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Weight reduction by aspiration therapy after 1 year of treatment | 1 year | Aspiration therapy using the AspireAssist® Aspiration Therapy System (Aspire Bariatrics Inc., King of Prussia, United States) for weight reduction in Asian subjects with obesity over a 12-month treatment period. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in blood pressure | 2 years | mean percent change in systolic and diastolic blood pressures during treatment (aspiration therapy + lifestyle therapy) period compared to control (lifestyle therapy only) period, and in the AT group compared to the control group |
| Change in Serum Lipids | 2 years | mean percent change serum lipids (triglyceride, HDL-cholesterol and LDL-cholesterol concentration) during treatment (aspiration therapy + lifestyle therapy) period compared to control (lifestyle therapy only) period, and in the AT group compared to the control group |
| Change in Mean Hemoglobin A1c | 2 years | change in mean hemoglobin A1C (only subjects with T2 diabetes at baseline) during treatment (aspiration therapy + lifestyle therapy) period compared to control (lifestyle therapy only) period, and in the AT group compared to the control group |
| Change in serum leptin | 2 years | change in mean serum leptin levels during treatment (aspiration therapy + lifestyle therapy) period compared to control (lifestyle therapy only) period, and in the AT group compared to the control group |
| Change in serum peptide YY | 2 years | change in mean serum peptide YY levels during treatment (aspiration therapy + lifestyle therapy) period compared to control (lifestyle therapy only) period, and in the AT group compared to the control group |
| Change in serum gastric inhibitory polypeptide | 2 years | change in mean serum gastric inhibitory polypeptide levels during treatment (aspiration therapy + lifestyle therapy) period compared to control (lifestyle therapy only) period, and in the AT group compared to the control group |
| Change in serum glucagon-like peptide 1 | 2 years | change in mean serum glucagon-like peptide 1 levels during treatment (aspiration therapy + lifestyle therapy) period compared to control (lifestyle therapy only) period, and in the AT group compared to the control group |
| Change in serum amylin | 2 years | change in mean serum amylin levels during treatment (aspiration therapy + lifestyle therapy) period compared to control (lifestyle therapy only) period, and in the AT group compared to the control group |
| Change in serum pancreatic polypeptide | 2 years | change in mean serum pancreatic polypeptide levels during treatment (aspiration therapy + lifestyle therapy) period compared to control (lifestyle therapy only) period, and in the AT group compared to the control group |
| Change in serum cholecystokinin | 2 years | change in mean serum cholecystokinin levels during treatment (aspiration therapy + lifestyle therapy) period compared to control (lifestyle therapy only) period, and in the AT group compared to the control group |
| Change in serum insulin | 2 years | change in mean serum insulin levels during treatment (aspiration therapy + lifestyle therapy) period compared to control (lifestyle therapy only) period, and in the AT group compared to the control group |
| Change in serum ghrelin | 2 years | change in mean serum ghrelin levels during treatment (aspiration therapy + lifestyle therapy) period compared to control (lifestyle therapy only) period, and in the AT group compared to the control group |
| Change in serum fibroblast growth factor 19 | 2 years | change in mean serum fibroblast growth factor 19 levels during treatment (aspiration therapy + lifestyle therapy) period compared to control (lifestyle therapy only) period, and in the AT group compared to the control group |
| Change in perceived appetite / satiety | 2 years | Using the control of eating questionnaire |
| Change in depressive symptoms | 2 years | Patient Health Questionnaire |
| Change in anxiety symptoms | 2 years | State-Trait Anxiety Inventory (STAI) |
| Change in eating behavior | 2 years | Eating Disorder Examination (EDE-Q) |
| Change in psychosocial functioning | 2 years | Obesity Related Psychological Problem Scale (OP Scale) |
| Electrolyte disturbances | 2 years | Number of treatment group subjects with hypokalemia, hypokalemia requiring oral replacement therapy and hypokalemia requiring in-patient care |
| Micronutrient disturbances | 2 years | Number of treatment group subjects with iron / vitamin B12 / folate deficiencies, with iron / vitamin B12 / folate deficiencies requiring oral replacement therapy and with iron / vitamin B12 / folate deficiencies requiring in-patient care |
| Adverse events | 2 years | The incidence of procedure-related, device-related, and therapy-related adverse events unrelated to electrolyte or micronutrient disturbances will be measured, as well as the incidence of device related, or unrelated, serious adverse events, including unanticipated adverse device effects. Also, the development of adverse eating behaviors will be assessed. |
| Sustainability of weight reduction (if any) with removal of the A-tube after the treatment period | 1 year | Mean weight gain during the first year after removal of the A-tube in the AT group |
| Change in serum C-peptide | 2 years | change in mean serum C-peptide levels during treatment (aspiration therapy + lifestyle therapy) period compared to control (lifestyle therapy only) period, and in the AT group compared to the control group |
Countries
Hong Kong
Contacts
Primary ContactMichele MA Yuen, MBBS
Backup ContactCarol HY Fong, MSc Stat
Outcome results
None listed